Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

BRAF; solute carrier family 31 copper transporters member 1 (SLC31A1; CTR1)

Cell culture and mouse studies suggest copper chelation could help treat cancers with oncogenic BRAF mutations. In mouse embryonic fibroblasts or melanoma cells expressing BRAF V600E, Ctr1-/- cells had less growth than Ctr1+/+ cells. In mouse models of BRAF-mutant lung cancer, Ctrl1 knockout or the copper chelator tetrathiomolybdate (TTM) decreased tumorigenesis and increased survival compared with no alteration or with vehicle. Ongoing studies include a Phase I clinical trial assessing the efficacy of the copper chelator trientine with the BRAF inhibitor vemurafenib.
Roche, Daiichi Sankyo Co. Ltd. and Chugai Pharmaceutical Co. Ltd. market Zelboraf vemurafenib to treat melanoma.
Valeant Pharmaceuticals International Inc. and Kadmon Corp. LLC market Syprine trientine hydrochloride to treat Wilson's disease.

SciBX 7(18); doi:10.1038/scibx.2014.517
Published online May 8, 2014

Provisional patent application filed; unlicensed

Brady, D.C. et al. Nature; published online April 9, 2014;
doi:10.1038/nature13180
Contact: Chris M. Counter, Duke University School of Medicine, Durham, N.C.
e-mail:

chris.counter@duke.edu